Titanovo Logo
Back to Cell Types

A2780Homo sapiens (Human)Cancer cell line

Also known as: A-2780, 2780, A2780S, A2780par

🤖 AI SummaryBased on 13 publications

Quick Overview

Human ovarian cancer cell line with cisplatin resistance and drug resistance mechanisms.

Detailed Summary

The A2780 cell line is a human ovarian cancer cell line derived from a patient with high-grade serous ovarian cancer. It is widely used in research to study drug resistance mechanisms, particularly in response to platinum-based chemotherapies like cisplatin and carboplatin. A2780 exhibits intrinsic resistance to these drugs, making it a valuable model for investigating the molecular basis of chemoresistance. Research has shown that A2780 and its derivatives, such as A2780-cp, display altered glycosylation patterns and gene expression profiles associated with drug resistance. These changes include upregulation of fucosyltransferases and glycosyltransferases, as well as modifications in glycan structures that may contribute to resistance. Additionally, A2780 has been used to study the role of the Wnt/β-catenin and integrin signaling pathways in drug resistance. The cell line is also utilized in proteomic and transcriptomic analyses to identify potential therapeutic targets and biomarkers for ovarian cancer.

Research Applications

Drug resistance mechanismsChemotherapy responseGlycosylation patternsGene expression profilingProteomic analysisSignaling pathway investigation

Key Characteristics

Cisplatin resistanceCarboplatin resistanceAltered glycosylationUpregulated fucosyltransferasesModified glycan structuresWnt/β-catenin pathway involvementIntegrin signaling pathway changes
Generated on 6/15/2025

Basic Information

Database IDCVCL_0134
SpeciesHomo sapiens (Human)
Tissue SourceOvary[UBERON:UBERON_0000992]

Donor Information

Age CategoryUnknown
SexFemale

Disease Information

DiseaseOvarian endometrioid adenocarcinoma
LineageOvary/Fallopian Tube
SubtypeEndometrioid Ovarian Cancer
OncoTree CodeEOV

DepMap Information

Source TypeECACC
Source IDACH-000657_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleATMp.Pro604Ser (c.1810C>T)Unspecified-from parent cell line A2780
MutationSimplePTENp.Lys128_Arg130del (c.383_391del9)Unspecified-from parent cell line A2780

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,11
D13S317
12,13
D16S539
11,12,13
D18S51
16,18
D19S433
12
D21S11
28
D2S1338
21,22
D3S1358
14,16
D5S818
11,12
D7S820
10
D8S1179
15,17
FGA
19,24
Penta D
8,9
Penta E
10,13
TH01
6
TPOX
8,10
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Nat. Commun. 7:12645.1-12645.14(2016).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Genomic characterization of cisplatin response uncovers priming of cisplatin-induced genes in a resistant cell line.

Golan Berman H., Chauhan P., Shalev S., Hassanain H., Parnas A., Adar S.

Int. J. Mol. Sci. 22:5814.1-5814.14(2021).

DOIPubMedPMC

Transcriptome remodeling in gradual development of inverse resistance between paclitaxel and cisplatin in ovarian cancer cells.

Siatkowski I., Goralski M., Synowiec A., Handschuh L.

Int. J. Mol. Sci. 21:9218.1-9218.30(2020).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.

Brebi P.

Biol. Res. 52:13.1-13.13(2019).

DOIPubMedPMC

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

DOIPubMedPMC

Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp.

Zhao R., Qin W.-J., Qin R.-H., Han J., Li C., Wang Y.-S., Xu C.-J.

Clin. Proteomics 14:20.1-20.10(2017).

DOIPubMedPMC

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Anderson M.E.

Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).

DOIPubMedPMC

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Parker R.J., Eastman A., Bostick-Bruton F., Reed E.

J. Clin. Invest. 87:772-777(1991).

DOIPubMedPMC

Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.

Ozols R.F.

Jpn. J. Cancer Res. 77:941-945(1986).

DOIPubMed

Effect of the tiapamil analog RO11-2933 on cellular sensitivity to antitumor drugs in sensitive and multidrug resistant human ovarian cancer cells.

Mazzoni A., Trave F., Canti G., Franco P.

Anticancer Res. 9:367-371(1989).

PubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Ozols R.F.

Cancer Res. 47:414-418(1987).

PubMed

Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

Grotzinger K.R., McKoy W.M., Winker M.A., Ozols R.F.

Cancer Res. 45:2110-2115(1985).

PubMed

Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F.

Science 224:994-996(1984).

DOIPubMed

Differential expression of the amv gene in human hematopoietic cells.

Aaronson S.A., Wong-Staal F.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).

DOIPubMedPMC

Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis.

Workman P.

Int. J. Cancer 59:94-102(1994).

DOIPubMed

Reversal of 'atypical'-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.

Russo P.

Oncol. Res. 5:311-323(1993).

PubMed

p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.

Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.

Gynecol. Oncol. 60:72-80(1996).

DOIPubMed

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Cancer Res. 57:850-856(1997).

PubMed

Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.

Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J.

Cancer Res. 60:6281-6287(2000).

PubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Auersperg N., Birrer M.J.

Oncogene 21:4435-4447(2002).

DOIPubMed

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

DOIPubMed

High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.

Lee C.-H., Ben-Dor A., Barrett M.T., Squire J.A.

Genes Chromosomes Cancer 47:427-436(2008).

DOIPubMed

Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.

Scambia G., Rotilio D.

J. Proteome Res. 8:1902-1912(2009).

DOIPubMed

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Oncol. Rep. 23:1021-1026(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Genomic complexity and AKT dependence in serous ovarian cancer.";

Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Cancer Discov. 2:56-67(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

DOIPubMedPMC

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Miyazaki K.

Hum. Pathol. 43:2197-2206(2012).

DOIPubMed

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

DOIPubMedPMC

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

DOIPubMedPMC

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

DOIPubMedPMC

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

DOIPubMedPMC

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

DOIPubMedPMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.

Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.

Int. J. Oncol. 46:2389-2398(2015).

DOIPubMed

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

J. Proteomics 139:77-83(2016).

DOIPubMed

Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Data Brief 7:1302-1305(2016).

DOIPubMedPMC

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Noonan A.M., Annunziata C.M.

Gynecol. Oncol. 142:332-340(2016).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Web Resources

dpsc.ccbr.utoronto.cathermofisher.comtcpaportal.orgculturecollections.org.uk